

Dear Chris

Please find below comments from SHTAC on the ACD. Our comments are points of correction rather than comments applicable to the general headings as suggested in Kate's email.

regards

Comments from Southampton Health Technology Assessments Centre (SHTAC)

- Point 3.11 - Suggest removing the words 'both comparators' from the end of the sentence as the (single) comparator is the combination of adefovir and lamivudine, rather than the two separately.
- Point 3.12, line six please add 'scenario' between 'exploratory' and 'analyses'.
- Point 3.13 line 1, and Point 3.14 line 3, should be scenario rather than sensitivity analyses
- Point 4.7, page 14 sentence "The Committee agreed with the view that the model of HBeAg-positive chronic hepatitis B could be limited to a short treatment duration because a significant proportion of people could be expected to experience seroconversion and thus stop receiving treatment. The term 'significant' may be a bit of an over-statement. In the model in the entecavir arm it is assumed that 18% seroconvert in the 1st year and 10% seroconvert in the 2nd year. Even assuming that nobody seroreverts, less than 30% of patients would not constitute a significant proportion to terminate treatment.
- Point 4.8, line 12 suggest add 'scenario' between 'exploratory' and 'analyses'